NVE Corporation (NVEC) - 10-K Filing Summary
Business Context and Reporting Period
This filing covers the fiscal year ended March 31, 2025. NVE Corporation develops and sells spintronic devices (sensors, couplers, and MRAM) used for data acquisition, transmission, and storage. The company operates in the Industrial Internet of Things (IIoT), medical devices, and power conversion markets. NVE is a non-accelerated filer and a smaller reporting company with a market capitalization of approximately $265 million as of September 30, 2024.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Total Revenue | $25.87 million | $29.80 million |
| Gross Profit | $21.64 million | $23.03 million |
| Gross Margin | 83.6% | 77.3% |
| Net Income | $15.06 million | $17.12 million |
| Diluted EPS | $3.11 | $3.54 |
| Operating Cash Flow | $14.31 million | $18.25 million |
| Cash & Cash Equivalents | $8.04 million | $10.28 million |
| Marketable Securities | $47.90 million | $52.55 million |
| Total Debt | $0 (No long-term debt) | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 13.2% year-over-year, driven primarily by a 15.7% drop in product sales due to reduced purchases by existing customers.
- R&D Growth: Contract research and development revenue increased 112% to $1.24 million, partially offsetting the decline in product sales.
- Margin Expansion: Gross margin improved to 83.6% from 77.3%, attributed to a more profitable product mix and a higher proportion of direct sales versus distributor sales.
- Expense Increase: Total operating expenses rose 25.1%, with R&D expenses up 33.1% due to new product development and SG&A up 13.4% due to increased sales and marketing activities.
- Net Income: Net income decreased 12.0% to $15.06 million, reflecting lower revenue and higher operating expenses, despite the improved gross margin.
Guidance, Outlook, and Risks
Outlook and Capital Allocation: Management plans to significantly increase fixed asset purchases in fiscal 2026 (estimated $2.0M–$3.0M) to support production capacity and new product development. The company declared a quarterly cash dividend of $1.00 per share on May 7, 2025, payable May 30, 2025. Dividends are funded by operating cash flow and marketable security maturities.
Key Risks and Contingencies:
- Customer Concentration: Two customers accounted for 35% and 19% of revenue in fiscal 2025. The loss of a major customer could materially harm the business.
- Supply Chain: The company relies on single-source suppliers for critical raw silicon wafers and packaging services, creating vulnerability to supply interruptions, tariffs, or geopolitical issues.
- Marketability of Securities: Approximately 75% of total assets are held in marketable securities. While currently high-grade, these are subject to interest rate risk and potential unrealized losses.
- Product Liability: Products used in medical devices expose the company to potential liability claims, though indemnification agreements exist with certain customers.
Investor Verification Checklist
- Customer Concentration: Verify the status of contracts with the top two customers (35% and 19% of revenue) and the renewal terms of the Abbott Laboratories agreement expiring December 31, 2025.
- Supply Chain Resilience: Assess the company's inventory buffers and contingency plans for single-source wafer and packaging suppliers.
- Dividend Sustainability: Review the ratio of cash dividends paid ($19.3M) against operating cash flow ($14.3M) to ensure long-term sustainability without eroding the investment portfolio.
- Capital Expenditure Plans: Monitor the execution of the planned $2M–$3M capital expenditure increase in fiscal 2026 and its impact on cash reserves.
- Marketable Securities: Evaluate the credit quality and duration of the $47.9M portfolio of marketable securities in the context of current interest rate environments.